Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Overall Survival

A measure of the time until death from any cause.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression‐free survival, as… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
Highly Cited
2017
Highly Cited
2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
BACKGROUND Nivolumab combined with ipilimumab resulted in longer progression‐free survival and a higher objective response rate… Expand
  • table 1
  • figure 1
  • figure 3
  • table 2
Highly Cited
2015
Highly Cited
2015
Improved overall survival in melanoma with combined dabrafenib and trametinib.
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Review
2011
Review
2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more… Expand
  • table 1
  • figure 3
  • table 2
Highly Cited
2010
Highly Cited
2010
Improved survival with ipilimumab in patients with metastatic melanoma.
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Highly Cited
2009
Highly Cited
2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2009
Highly Cited
2009
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
PURPOSE Three-year disease-free survival (DFS) was significantly improved in patients who had undergone resection with curative… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2008
Highly Cited
2008
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
PURPOSE As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with a prognostic and predictive role… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
2005
Highly Cited
2005
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
BACKGROUND Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
1995
Highly Cited
1995
Diet and overall survival in elderly people
Abstract Objective: To assess the influence of a specific dietary pattern on overall survival. Design: Cohort study. Setting… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE